Ignite Creation Date:
2024-05-06 @ 4:42 PM
Last Modification Date:
2024-10-26 @ 2:14 PM
Study NCT ID:
NCT05066672
Status:
RECRUITING
Last Update Posted:
2023-11-09
First Post:
2021-09-23
Brief Title:
Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression
Sponsor:
Navitor Pharmaceuticals Inc
Organization:
Navitor Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 2 Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the efficacy and safety of NV-5138 in adults with TRD
Detailed Description:
The is a multicenter randomized double-blind flexible- dose placebo-controlled parallel design of adjunctive NV-5138 in adults with TRD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SPN820 | OTHER | Supernus Pharmaceuticals Inc | None |